One-leg exercise training to improve muscle energy and function in adults with mitochondrial myopathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study uses a 3-4 week supervised unilateral high-intensity interval training program (10 sessions) with the trained leg randomized and the opposite leg serving as an internal untrained control. Participants complete comprehensive baseline testing of strength, aerobic capacity, body composition, and physical activity before the intervention. Muscle biopsies are taken from both legs after the training period to measure mitochondrial respiratory function, energy pathways, stress responses, and markers of muscle-nerve communication. Comparing trained versus untrained muscle within individuals and between patients and matched healthy controls will clarify molecular adaptations to exercise in mitochondrial myopathy.

Why it matters

Who can join: the full rules

Eligibility criteria for Mitochondrial Myopathy-group:

Inclusion Criteria

* Known mtDNA or nuclear (nDNA) mutations
* Age above or equal to 18 years

Exclusion Criteria:

* Medical conditions which deem the MM patient unfit to complete the study
* Current use of medications known to interact with outcome measures. (see below)
* Pregnancy
* The participant is for any other reason unlikely to complete the study

Inclusion Criteria for healthy controls

* Age above or equal to 18 years

Exclusion Criteria:

* Chronic medical conditions suspected to influence outcome measures
* Frequent use of medicine
* Pregnancy
* The participant is for any other reason unlikely to complete the study

Where it's running

• University of Copenhagen, Dept of Biomedical Sciences
  Copenhagen, Denmark Recruiting

Study contacts

• Study coordinator: Tue L Nielsen, MD
• Email: tue.leth.nielsen.01@regionh.dk
• Phone: +45 3545 8748

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metabolic and Functional Study of γδ T Cells in Critically Ill Patients

  Researchers will look at how γδ T cells behave in severely ill patients, including those with sepsis, to see how their metabolism and function change.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Outside of the US · NCT07680816

• Open-label extension to test KL1333 long-term safety and benefit for primary mitochondrial disease

  This extension study will see if KL1333 can be safely used long-term and whether it helps reduce fatigue and improve daily living in adults with primary mitochondrial disease who previously took KL1333 or placebo.

  Recruiting at 23 sites Phase 2 Pharming Technologies B.V. · Akron, Ohio and 22 other locations · NCT07514338

• Using transcriptomic analysis to diagnose mitochondrial diseases

  This study is testing a new way to diagnose mitochondrial diseases by looking at gene activity in patients' cells to help those who haven't been diagnosed yet.

  Recruiting at 2 sites Centre Hospitalier Universitaire de Nice · Nice, Alpes-maritimes and 1 other locations · NCT06621732

• Observing the natural history of mitochondrial diseases

  This study is tracking 400 people with mitochondrial diseases and 100 healthy individuals over 10 years to see how the disease affects them and to help improve future diagnosis and treatment.

  Recruiting Neuroscience Research Australia · Randwick, New South Wales · NCT06504433

• Sonlicromanol for symptoms of primary mitochondrial disease due to the m.3243A>G mutation

  This will test whether taking sonlicromanol twice daily for one year can reduce fatigue and improve balance and leg strength in adults with the m.3243A>G mitochondrial mutation.

  Recruiting at 7 sites Phase 3 Khondrion BV · Boston, Massachusetts and 9 other locations · NCT06451757

• Transplantation of MNV-201 for treating Pearson Syndrome in children

  This study is testing a new cell therapy called MNV-201 to see if it can help children with Pearson Syndrome feel better and manage their symptoms.

  Recruiting Phase 2 Minovia Therapeutics Ltd. · Ramat Gan, Israel · NCT06017869

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.